Resistance Oncology ApS Financials, key figures and credit report
Gross profit - 410.6 kDKK FY 2025 -2,513.4% vs 2024
EBIT - 421.1 kDKK FY 2025 -2,580.2% vs 2024
Net debt -0.8 kDKK FY 2025 +56.1% vs 2024
Quick ratio 1.0 FY 2025 +0 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -10.14 | -11.97 | -21.00 | -15.71 | - 410.61 |
| Total depreciation | -10.50 | ||||
| EBIT | -10.14 | -11.97 | -21.00 | -15.71 | - 421.11 |
| Other financial income | 0.05 | 0.20 | 0.48 | ||
| Other financial expenses | -0.91 | -1.17 | -6.09 | -8.40 | -1.28 |
| Net income from associates (fin.) | -0.93 | -37.81 | - 335.98 | ||
| Pre-tax profit | -11.04 | -13.14 | -27.98 | -61.73 | - 757.89 |
| Income taxes | 2.43 | 2.89 | 5.95 | 5.26 | 92.82 |
| Net earnings | -8.62 | -10.25 | -22.03 | -56.47 | - 665.07 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible rights | 289.50 | ||||
| Intangible assets total | 289.50 | ||||
| Tangible assets total | |||||
| Holdings in group member companies | 39.07 | 281.26 | 57.33 | ||
| Investments total | 39.07 | 281.26 | 57.33 | ||
| Long term receivables total | |||||
| Inventories total | |||||
| Current amounts owed by group member comp. | 5.26 | ||||
| Prepayments and accrued income | 1.02 | ||||
| Current other receivables | 2.19 | 2.49 | 0.57 | 2.56 | 76.74 |
| Current deferred tax assets | 2.43 | 2.89 | 5.95 | 5.26 | 99.94 |
| Short term receivables total | 4.62 | 5.38 | 7.54 | 7.82 | 181.94 |
| Cash and bank deposits | 1.48 | 1.44 | 2.55 | 131.12 | 7.02 |
| Cash and cash equivalents | 1.48 | 1.44 | 2.55 | 131.12 | 7.02 |
| Balance sheet total (assets) | 6.10 | 6.82 | 49.16 | 420.20 | 535.79 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 51.00 | 51.00 | 51.00 | 51.00 | 51.00 |
| Retained earnings | -73.56 | -82.18 | -92.43 | 285.54 | 939.70 |
| Profit of the financial year | -8.62 | -10.25 | -22.03 | -56.47 | - 665.07 |
| Shareholders equity total | -31.18 | -41.43 | -63.46 | 280.07 | 325.63 |
| Provisions | 23.58 | ||||
| Non-current liabilities total | |||||
| Current trade creditors | 8.00 | 9.00 | 9.50 | 10.75 | 180.33 |
| Current owed to group member | 29.28 | 39.25 | 103.12 | 129.38 | 6.25 |
| Current liabilities total | 37.28 | 48.25 | 112.62 | 140.13 | 186.58 |
| Balance sheet total (liabilities) | 6.10 | 6.82 | 49.16 | 420.20 | 535.79 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated